Economic Impact of Palifermin on the Costs of Hospitalization for Autologous Hematopoietic Stem-Cell Transplant: Analysis of Phase 3 Trial Results  by Elting, Linda S. et al.
E
o
S
T
I
s
h
Biology of Blood and Marrow Transplantation 13:806-813 (2007)
 2007 American Society for Blood and Marrow Transplantation
1083-8791/07/1307-0001$32.00/0
doi:10.1016/j.bbmt.2007.03.004
8conomic Impact of Palifermin on the Costs
f Hospitalization for Autologous Hematopoietic
tem-Cell Transplant: Analysis of Phase 3
rial Results
Linda S. Elting,1 Ya-Chen Tina Shih,1 Patrick J. Stiff,2 William Bensinger,3 Scott B. Cantor,1
Catherine Cooksley,1 Ricardo Spielberger,4 Christos Emmanoulides5
1University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2Cardinal Bernardin Cancer Center, Loyola
University Chicago, Maywood, Illinois; 3Fred Hutchinson Cancer Research Center, Seattle, Washington; 4City of
Hope National Medical Center, Duarte, California; 5Interbalkan Hospital, Thessaloniki, Greece
Correspondence and reprint requests: Linda S. Elting, DrPH, Health Services Research, Department of
Biostatistics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 447, Houston,
TX 77030-4009 (e-mail: lelting@mdanderson.org).
Received October 6, 2006; accepted March 5, 2007
ABSTRACT
A double-blind, randomized trial showed that, compared with placebo, palifermin (recombinant human keratino-
cyte growth factor) reduced the frequency and duration of oral mucositis in patients with hematologic malignancies
undergoing high-dose chemotherapy and total-body irradiation with autologous stem-cell support. This previously
published study also showed a significant reduction in the incidence of adverse subsequent outcomes. The objective
of this study was to estimate the impact of palifermin prophylaxis on hospital costs of transplantation in the trial.
This was a retrospective, economic analysis of estimated costs for a previously published clinical trial. Costs were
not collected during the trial. Therefore, we estimated the direct medical costs of hospitalization using hospital
charges from similar patients’ hospitalization charges selected from the National Inpatient Sample, a population-
based, nationally representative sample of hospital claims. Costs were estimated from charges using Medicare’s
state-specific cost-to-charge ratios. These cost estimates were applied to the outcome data (incidence of febrile
neutropenia, bacteremia/fungemia, or pneumonia, and use of total parenteral nutrition) from the clinical trial.
Patients were those with hematologic malignancies who received high-dose chemotherapy and total-body irradi-
ation with autologous stem cell transplant. We compared the estimated total hospital costs (in 2005 United States
dollars) incurred by patients who received palifermin in the clinical trial with those incurred by patients who
received placebo. Costs were analyzed from the provider’s perspective. The mean cost of a hospital day in this
population varied between $2,834, when no adverse outcomes occurred, and $4,663, when all 4 outcomes occurred.
Reductions in adverse outcomes and their associated hospital stay offset the acquisition price of palifermin. A
nonsignificant mean savings of $3,595 per patient (95% confidence interval: $2,090-$5,103) was observed. In
sensitivity analyses, this observation was robust to all plausible values of per diem hospital costs and hypothetic per
diem outpatient costs. In addition to its previously demonstrated clinical benefit, palifermin prophylaxis offers a
favorable economic profile among patients with hematologic malignancies who receive total body irradiation and
autologous stem cell support.
© 2007 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Oral mucositis (OM) is a frequent and often
evere complication in patients who are treated with
ematopoietic stem cell transplantation (HSCT). A B
06igher incidence rate of OM is associated with con-
itioning regimens that include total-body irradia-
ion (TBI) in combination with high-dose chemo-
herapy than when chemotherapy is used alone [1].
ecause of the toxicity of high-dose, myeloablative
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Economic Impact of Palifermin 807hemotherapy, the condition can be especially de-
ilitating for patients with hematologic malignan-
ies who undergo HSCT [2]. A number of studies
ave demonstrated that approximately 75% of all
atients who receive HSCT experience severe OM
grades 3 and 4) [3-6]. In this setting, the condition
s associated with signiﬁcantly poorer clinical out-
omes, such as febrile neutropenia (FN), bactere-
ia, and prolonged use of total parenteral nutrition
TPN). In addition, the costs associated with OM
an be excessive because of increased utilization of
ntibiotics, pain medication, TPN, and longer hos-
ital stays [2-7]. In a multinational pilot study, So-
is et al. [2] reported that hospital charges among
SCT recipients with OM were nearly $43,000
igher than patients who did not experience the
ondition.
Recently, palifermin (recombinant human kera-
inocyte growth factor, Kepivance [Amgen, Thou-
and Oaks, CA]) was approved based in part on a
andomized, double-blind, placebo-controlled clin-
cal trial that showed signiﬁcant reductions in the
ncidence and duration of severe OM in patients
ith hematologic malignancies who received my-
lotoxic therapy including TBI and HSCT [8]. In
his trial by Spielberger et al. [8], palifermin was
lso associated with a signiﬁcant reduction in the
ncidence of important subsequent outcomes (FN,
se of TPN, and blood borne infections), decreased
pioid analgesic use, and a 2-day reduction in the
verage length of hospital stay [9]. In addition,
alifermin signiﬁcantly reduced the incidence of the
orld Health Organization (WHO) grade 4 OM
20% vs 62%, p  0.001), which is associated with
ncreased resource utilization. A recent, non ran-
omized study, conducted in patients with hemato-
ogic cancers undergoing HSCT without TBI con-
rmed these ﬁndings; the incidence of severe
ucositis and the length of hospitalization were
igniﬁcantly lower among patients who received
alifermin compared with historic controls [10].
We hypothesized that the signiﬁcant reductions in
ospitalization associated with costly subsequent out-
omes among patients treated with palifermin might
ffset the acquisition cost of the drug or lead to cost
avings. Cost data were not collected during the ran-
omized trial, but the consistency in the frequency of
mportant subsequent outcomes (particularly FN, in-
ections, and TPN use) in the trial and in previ-
us studies suggested a method for estimating cost.
herefore, we conducted a retrospective cost analysis
f palifermin in the transplant setting, combining out-
ome data from the previously published clinical trial
nd cost data from a nationally representative data-
ase. wATIENTS AND METHODS
Data were obtained from 2 sources. Length of stay
nd clinical outcomes were obtained from the phase 3
rial [8]. Because costs were not collected prospec-
ively during the clinical trial and were not available
etrospectively, the cost of hospital days was estimated
rom the National Inpatient Survey (NIS) and applied
o the patients in the clinical trial.
The phase 3 trial included 212 patients with he-
atologic cancers. One hundred six patients were
andomly assigned to receive intravenous palifermin
60 g per kilogram of body weight per day) for 3
onsecutive days before receiving TBI and high-dose
hemotherapy and for 3 days after infusion of auto-
ogous stem cells. The other 106 patients followed the
ame conditioning and transplantation protocol but
ere randomly assigned to receive placebo intrave-
ously [8].
The NIS is a random sample of claims from
ospital discharges in the United States, weighted
o be representative of the hospitals and population
10]. It is the largest collection of encounter-level,
ll-payer hospital cost and care data in the United
tates. The NIS database includes discharges from
ll public and private hospitals, except federal and
ilitary centers, in 38 participating states. Report-
ng of all discharges is legislatively mandated in
hese states and discharges are evaluated at both
ospital and patient levels to ensure that the entire
ountry is represented. The NIS was created as part
f the Healthcare Cost and Utilization Project. It is
ublicly available through the Agency for Health-
are Research and Quality and has been used exten-
ively to study the cost and quality of hospital care
n the United States [11].
nalytic Strategy
We compared the average cost of hospitalization
f the patients who received palifermin to the average
ost of those who received placebo. To ensure that the
osts obtained from the NIS reﬂected the care deliv-
red to the trial patients as closely as possible, we
atched the NIS cohort to the trial patients on he-
atologic malignancy, type of cells received, use of
BI, and presence or absence of subsequent outcomes
s follows.
First, we classiﬁed each patient in the trial
y treatment strategy (palifermin versus placebo)
nd by presence or absence of subsequent outcomes
f OM (none, FN, TPN, bacteremia, pneumonia,
nd combinations of outcomes) (Table 1). Blood
orne infections were deﬁned a priori in the origi-
al trial’s protocol and collected prospectively as
econdary outcomes. In the original publication
hey were reported as a single outcome. However,
e categorized individual outcomes to apply more
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L. S. Elting et al.808recise costs from the NIS. As a result of this
rocess, we analyzed culture-proved bacteremia/
ungemia and pneumonia separately. We did not
ategorize 5 episodes of “blood-borne infection”
wing to lack of information from case report
orms. These patients were categorized by their
ther outcomes as follows. On the palifermin arm, 2
ases with coagulase negative Staphylococci, but
ithout positive blood cultures or a site of infection,
ere categorized by their other outcomes, FN in 1
ase and both FN and TPN in the other. Also on
he palifermin arm, 1 case of “sepsis” without pos-
tive blood cultures was classiﬁed as FN. On the
lacebo arm, 1 case of “sepsis” without positive
lood cultures was classiﬁed as FN and TPN, and 1
ase of “bacterial infection” without a positive blood
ulture and without an organism was classiﬁed
s FN.
Next, we selected patients with hematologic ma-
ignancies who underwent autologous HSCT after
BI during the same years that the clinical trial was
onducted (2001-2002) from the NIS database us-
ng appropriate diagnosis and procedure codes (Ta-
le 2). We classiﬁed these patients by the same
utcomes used to classify the clinical trial patients
none, FN, TPN, bacteremia, pneumonia, and com-
able 1. Adverse Clinical Outcomes*
Outcome
Palifermin N  106
No. (%) Affected
Length
D
one 13 (12) 19.
N only 52 (49) 20.
PN only 10 (9) 22.
ACT only 1 (1) 11.
N only 1 (1) 10.
PN  FN 18 (17)a 22.
PN  BACT 2 (2) 24.
N  BACT 3 (3) 18.
N  PN 3 (3) 28.
PN, FN, BACT 3 (3) 24.
PN, FN, PN 0
PN, FN, BACT, PN 0
N indicates febrile neutropenia; TPN, total parenteral nutrition; B
Outcomes derived from clinical trial [8,17].
P  .005.
able 2. Codes Used to Identify Patient and Treatment Groups and Cl
Group Category
alignancy Hematologic 196
ransplant type Autologous 41.0
ransplanted cells Stem cells 41.0
onditioning Total body irradiation 92.2
utcomes Febrile neutropenia 288
Total parenteral nutrition 99.1
Bacteremia, Fungemia 038
Pneumonia 480.xx-487inations of outcomes), again using appropriate di-
gnosis or procedure codes. The cost of hospital-
zation was computed from this sample.
We assumed the perspective of the hospital (pro-
ider) for this analysis; thus, the cost of providing care
as of more interest than the charges billed. The NIS
atabase includes charges, not costs. Therefore, we
btained charges from the NIS based on the out-
omes, and transformed them into costs using state-
peciﬁc Medicare cost-to-charge ratios for operating
nd capital costs for urban centers [12]. These costs
ere adjusted to 2005 US dollars using the Consumer
rice Index for hospital services in urban areas, where
ost bone marrow transplants are performed [13].
rom this ﬁnal estimate, the mean cost per hospital
ay was computed for each outcome group (none, FN,
PN, bacteremia, pneumonia, and combinations of
utcomes).
We computed the estimates of cost for the pa-
ients in the clinical trial by multiplying the mean cost
er hospital day (from the NIS patients) by the num-
er of hospital days for each trial patient, matched on
utcome group. For trial patients who received pali-
ermin, we added the average sales price of palifermin
$8,250 per patient per 6-day course), which we ob-
Placebo N  106
Mean
) No. (%) Affected
Length of Stay Mean
Days (SD)
3) 3 (3) 15.00 (12.00)
6) 38 (36) 19.84 (10.17)
2) 5 (4) 22.20 (3.11)
0 —
0 —
4) 36 (34)† 24.0 (5.26)
2) 1 (1) 28.00 (—)
3) 3 (3) 16.67 (14.98)
6) 4 (4) 27.50 (6.86)
6) 12 (11) 25.75 (8.01)
3 (3) 26.00 (6.08)
1 (1) 22.00 (—)
bacteremia or fungemia; PN, pneumonia; SD, standard deviation.
utcomes in the National Inpatient Sample (NIS)
ICD 9 Codes NIS Data Type
.2x, 201.xx-208.xx, V10.6x, V10.7x, 238.7 Diagnosis
1, 41.04, 41.07, 41.09 Procedure
7, 41.05, 41.08 Procedure
6, 92.77, 92.29 Procedure
Diagnosis
Procedure
2.5, 117.9 Diagnosisof Stay
ays (SD
85 (7.8
50 (8.3
00 (3.9
00 (—)
00 (—)
11 (7.1
50 (2.1
33 (6.4
33 (6.6
33 (5.8
—
—
ACT,inical O
.x, 200
0, 41.0
4, 41.0
4, 92.2
.0
5
.xx, 11.0 Diagnosis
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Economic Impact of Palifermin 809ained from the Centers for Medicare and Medicaid
ervices [14].
We assumed that costs were distributed evenly
cross the entire hospital stay and that all providers
ould pay the average sales price for palifermin.
nalyses
We described the mean total costs and 95% con-
dence limits for patients who received palifermin or
lacebo and described differences in total costs using
inear regression. Standard errors were bootstrapped
o reduce the effect of extreme values of cost. Sensi-
ivity analyses, in the form of best-case and worst-case
cenarios, were conducted based on the 95% conﬁ-
ence limits around the mean total cost of hospital-
zation (also known as the Box method).
No data were available on the outpatient costs of
SCT after TBI. Therefore, our primary analysis
ncluded only the inpatient costs. Because some pa-
ients in the clinical trial were managed for all or part
f their transplant in the outpatient setting, our pri-
ary results reﬂect neither the total cost of transplant
or the difference in total cost of care between pali-
ermin and placebo. However, we conducted 2 sensi-
ivity analyses using hypothetic outpatient costs. For
oth analyses, we constructed a hypothetic 35-day
bservation time for each patient, approximating the
reatment schema in the trial. We computed the num-
er of outpatient days by subtracting the number of
ospital days from 35. In the ﬁrst analysis, we assigned
utpatient per diem costs as a percentage of each
atient’s inpatient per diem costs, reﬂecting the out-
omes and intensity of care required by each patient
hile in the hospital. In the second analysis, we as-
igned identical hypothetic per diem outpatient costs,
anging from $500-$3,000, to every patient. We then
omputed hypothetic total costs by summing esti-
ated inpatient costs and hypothetic outpatient costs.
n both analyses, ranges of plausible and extreme val-
es were examined.
Differences between proportions were described
sing 2-tailed chi-square tests. Differences in the
ean length of stays for patients on palifermin and
lacebo were described using 2-tailed t-tests.
The study was reviewed by the institutional review
oard at The University of Texas M.D. Anderson
ancer Center and determined to be exempt as it used
nly deidentiﬁed or public use datasets.
ESULTS
The 212 patients in the clinical trial were very
imilar to the 877 patients in the NIS population. The
istribution of age and gender was virtually identical
n the NIS cohort and clinical trial patients, but non-
ispanic whites were more common in the trial pop- clation (Table 3). Because some trial patients were
ransplanted in the outpatient setting, the mean length
f hospital stay was shorter in the clinical trial patients
22.8 days) than in the NIS sample (26.6 days). Be-
ause of our selection criteria, the NIS data included
nly those patients who received their transplants in
he hospital. The trial and NIS databases did not share
common measure of severity of illness. However the
groups were similar with respect to 2 related factors;
2% of trial patients had excellent performance status
90%) and 84% of NIS patients had no comorbid
llnesses. Patients with non-Hodgkin’s lymphoma and
ultiple myeloma predominated in both the trial
75.9%) and the NIS (70.6%) groups. However, mul-
iple myeloma patients were overrepresented in the
IS population compared with the trial population
35% versus 9%).
Based on the NIS data, the national mean cost per
ospital day for patients with hematologic malignan-
ies undergoing HSCT ranged from $2,834 (95%
onﬁdence interval [CI]  $2,255-$3,413), in the case
here no subsequent outcomes were present, to
4,663 (95% CI  $2,341-$6,985), in the case where
ultiple outcomes occurred, reﬂecting higher inten-
ity of services when multiple outcomes occurred.
onger hospitalizations were associated with multiple
dverse subsequent outcomes in the clinical trial pa-
ients as well. Most trial patients who had short hos-
italizations (2 weeks) had 0 or 1 subsequent out-
able 3. Comparison of Characteristics of Patients in Clinical Trial
nd National Inpatient Sample (NIS)
Characteristic
Clinical Trial
N  212
National
Inpatient
Sample
N  877
ge, mean years (95% CI) 46.4 (44.7-47.9) 47.6 (44.0-51.3)
ales, % (95% CI) 62 (55-68) 62 (56-67)
on-Hispanic White,
% (95% CI) 79 (73-84) 63 (50-76)
frican-American,
% (95% CI) 8 (5-13) 5 (1-10)
ispanic, % (95% CI) 8 (5-13) 10 (0-21)
sian, others, % (95% CI) 4 (2-8) 4 (0-8)
nknown, % (95% CI) 0 18 (4-31)
harlson comorbidity
score*  0 — 83.9 (78.4-88.2)
harlson comorbidity
score >1 — 16.1 (11.8-21.6)
arnofsky Performance
status** >90 82.1 (76.2-87.0) —
arnofsky Performance
status <90 17.9 (13.0-23.8) —
ospital stay, mean days
(95% CI) 21.7 (20.6-22.8) 26.6 (21.8-31.4)
I indicates conﬁdence interval.
Lower scores indicate fewer comorbid conditions [21].
*Higher scores indicate better performance status [22].omes, whereas those with long hospitalizations
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L. S. Elting et al.810ended to have several adverse outcomes (Figure 1)
ive patients on the palifermin arm and 6 on the
lacebo arm were never admitted to the hospital.
mong those who were admitted to the hospital, the
ean hospital length of stays differed between those
n palifermin (22.0 days; 95% CI  20.8-23.2 days)
nd placebo (23.7 days; 95% CI 22.4-25.0; P .06).
welve percent of patients on the palifermin arm and
nly 5% of patients on the placebo arm were admitted
or 2 weeks.
The estimated average total cost per patient for
hose treated with palifermin in the clinical trial
as $73,938 (95% CI  $69,031-$78,845) versus
77,533 (95% CI  $71,121-$83,948) for patients
ho received placebo (Figure 2) This analysis dem-
nstrated a modest savings of $3,595 per patient
reated with palifermin, after accounting for the
cquisition cost of palifermin. However, it is impor-
ant to note that the difference in mean costs was
ot statistically signiﬁcant (P  .39), suggesting that
lthough the addition of palifermin may not in-
rease cost, it may not reduce costs either. Inspec-
ion of the overlap in the 95% conﬁdence limits
upports this interpretation as well.
As can be seen from Table 1 and Figure 2, cost
avings or cost offset resulted from reduction in the
umber of patients who developed serious outcomes,
ot from shorter hospital stays when outcomes oc-
urred. For most outcome groups, the average cost
er patient increased with the addition of palifermin.
owever, far fewer patients on the palifermin arm
ere in the most costly outcome groups (those with
igure 1. Relationship between duration of hospitalization and
umber of adverse outcomes. Adverse outcomes include febrile
eutropenia, bacteremia, pneumonia, and total parenteral nutrition.ultiple adverse outcomes) than on the placebo arm t29 [27%] and 60 [57%], respectively; P  .001).
imilarly, 13 (12%) patients on the palifermin treat-
ent arm had none of the adverse OM outcomes (the
owest cost group) compared with only 3 (3%) on the
lacebo arm (P  .02).
Our results were robust to sensitivity analyses us-
ng best and worst case scenarios as well as plausible
alues of hypothetic outpatient costs. In the best-case
cenario (using the upper 95% conﬁdence limit for
ean cost), there was an estimated savings of $5,103
er patient treated with palifermin. In the worst-case
cenario (using the lower 95% conﬁdence limit for
ean cost of hospitalization), palifermin therapy was
ssociated with savings of $2,090 per patient. Using
ypothetic outpatient costs to compute a total cost,
onsigniﬁcant savings were observed across the entire
ange of outpatient per diem costs when these were
omputed as a percentage of inpatient costs (Table 4).
sing a standard per diem cost for every patient,
onsigniﬁcant savings were observed with palifermin
or all plausible values of outpatient per diem cost.
nly when outpatient per diem costs approached
3,000, a value higher than inpatient costs for 50%
f patients on the trial, was a nonsigniﬁcant excess cost
bserved.
ISCUSSION
Cytotoxic therapies induce a damaging sequence
f biologic events that prompt inﬂammation and
lceration of the epithelial mucosa [15]. As OM
rogresses, conﬂuent lesions erupt and expand with
acterial colonization and produce considerable
oxicity and pain. Injury to the oral mucosa provides
portal through which pathogens can enter the
loodstream and may lead to serious and potentially
atal infections, especially during periods of myelo-
uppression. In the presence of neutropenia, high-
rade mucositis may predispose patients to bactere-
ia [2,7,16].
Oral mucositis impedes nutrient intake because
ating and drinking become difﬁcult or impossible for
atients with high grades of the condition [15,17].
luid replacement therapy, liquid diets, and TPN are
igniﬁcantly more common during episodes of OM
nd further compound hospital costs. In a retrospec-
ive, random sample of 599 patients with solid tumors
nd lymphoma who developed chemotherapy-induced
yelosuppression, the investigators identiﬁed a 10-
old increase in utilization of TPN, hydration, and use
f opioids and a 2-fold increase in emergency room
isits for patients who experienced high grades of OM.
rades 3 and 4 OM were associated with incremental
osts of over $5,565 per chemotherapy cycle [7].
Oral mucositis is especially burdensome to pa-
ients who undergo HSCT and may affect as many as
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Economic Impact of Palifermin 8115% of all stem cell recipients [3-6]. In this popula-
ion, oral mucositis is typically seen in association with
ncreased risks of bleeding, fatigue, serious infection,
nd increased use of TPN, antibiotics, and pain med-
cation [2,15-17]. These complications can increase
osts considerably.
Figure 2. Cost estimat
able 4. Comparison of Hypothetical Total Costs Over 35 Days
Outpatient per Diem Cost Palifermin Mean Cost* (
of inpatient cost
10% $78,273 ($73,787-$82,
50% $95,614 ($92,281-$98,
75% $106,451 ($103,788-$10
90% $112,954 ($110,463-$11
ypothetical standard cost per patient
$500 $80,967 ($76,807-$85,
$1000 $87,995 ($84,382-$91,
$2000 $102,051 ($99,674-$104
$2500 $109,080 ($107,053-$11
$3000 $116,108 ($114,340-$11Mean cost  estimated inpatient cost  hypothetical outpatient cost forAlthough there have been agents available for
any years to prevent other side effects of antineo-
lastic therapies, such as nausea and vomiting, diar-
hea, anemia, and neutropenia, OM was historically
reated symptomatically. Conventional therapies, in-
luding a variety of rinses, topical anesthetics, and
he base-case scenario.
) Placebo Mean Cost* (95% CI) Difference Palifermin-Placebo
$81,781 ($75,573-$87,989) $3,508
$98,767 ($93,940-$103,592) $3,153
$109,381 ($104,933-$113,830) $2,930
$115,751 ($111,697-$119,804) $2,797
$83,945 ($78,088-$89,803) $2,978
$90,345 ($85,114-$95,597) $2,361
$103,176 ($99,349-$107,004) $1,125
$109,587 ($106,153-$113,020) $507
$115,997 ($113,030-$118,964) $11195% CI
760)
946)
9,115)
5,445)
126)
608)
,429)
1,107)
7,877)the 35-day observation period.
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L. S. Elting et al.812ucosal coating agents have been used, but have dem-
nstrated limited to no meaningful efﬁcacy [1,18,19].
owever, the introduction of palifermin may change
he oral mucositis therapeutic landscape. Palifermin’s
ffectiveness in reducing the incidence and duration of
evere OM and its clinically important outcomes
romises new opportunities for intervening in the
ourse of this serious condition. However, palifer-
in’s clinical potential comes at a considerable price,
urrently $8,250 per patient in the bone marrow
ransplant setting. This additional cost may be justi-
ed based solely on palifermin’s effectiveness, which
epresents a major clinical and quality of life improve-
ent. However, the additional cost would certainly be
ustiﬁed if it were offset by cost savings resulting from
ewer adverse outcomes of mucositis. The purpose of
his study was to estimate the additional cost or cost
avings of palifermin prophylaxis.
In the clinical trial population, use of palifermin
as associated with an estimated savings in hospital
osts of $3,595 per patient after accounting for the
dditional price of the drug. This observation was
obust in multiple sensitivity analyses. However, the
ifference in mean costs was not statistically signiﬁ-
ant and there was large overlap in the 95% conﬁ-
ence limits. These ﬁndings suggest that although
nalysis in the trial population showed modest savings,
se of palifermin would generally be considered cost-
eutral. The acquisition cost is likely offset by reduced
ospitalization, but signiﬁcant cost savings may not
ccur. We also showed that the acquisition of cost of
alifermin was offset as a result of a reduction in the
requency of adverse outcomes, particularly from sig-
iﬁcantly lower utilization of TPN, a costly interven-
ion. From both clinical and economic perspectives,
se of palifermin seems to be justiﬁed among patients
imilar in risk of OM to the clinical trial population.
These results should be interpreted in the light of
number of limitations to this analysis. First, cost data
ere unavailable for the patients in the clinical trial,
aking it necessary to use costs from patients in a
eparate database. These costs are nationally represen-
ative, and thus widely generalizable. However, they
re not speciﬁc to the patients in the trial. Second, in
onsideration of the information available in the NIS,
e assumed that charges were evenly distributed
cross the entire hospital stay and calculated the per
iem costs accordingly. This assumption may intro-
uce bias. If charges are highest in the ﬁrst few days of
ospitalization, then costs for discharges with longer
engths of stays may be over estimated. Because the
lacebo group had longer lengths of stay, this assump-
ion could have led to overestimation of placebo costs
nd overestimation of the cost savings of palifermin.
n contrast, if charges are higher during the later days
f hospitalization when adverse subsequent outcomes
ave occurred, this assumption could lead to overes- cimation of costs in patients with short hospitaliza-
ions and few adverse outcomes (ie, the palifermin
atients). It is impossible to determine the direction or
agnitude of this bias with the available data.
Third, our analysis considered the effectiveness of
alifermin only in terms of reduced cost of hospital-
zation. This strategy has the advantage of providing
ffordability information to providers who often re-
eive payments for bone marrow transplantation
BMT) on a capitated basis. The disadvantage of tak-
ng the provider’s perspective is that signiﬁcant im-
rovements in quality of life are not accounted for in
he analysis. Because OM signiﬁcantly compromises
he quality of life of BMT recipients, this is an impor-
ant concern. In the clinical trial, the worst grade of
ucositis was signiﬁcantly less frequent among those
ho received palifermin (20% versus 62%, P  .001)
8]. The median scores for soreness of the mouth and
hroat were signiﬁcantly lower (lower scores indicate
ess pain) in the palifermin group than the placebo
roup [8,20]. Patients treated with palifermin had sig-
iﬁcantly higher scores (higher scores indicate better
unctioning) for physical and functional well-being
ategories of the Functional Assessment of Cancer
herapy than those patients receiving placebo [8].
hese ﬁndings illustrate the impact of palifermin use
n quality of life; failure to account for that impact
eads to underestimation of the beneﬁts of palifermin.
It is prudent to carefully consider the clinical
etting when interpreting our results. In other BMT
ettings, particularly those without TBI, the cost
roﬁle may not be as favorable as shown in this
opulation. The clinical ﬁndings of the original trial
ere recently conﬁrmed in a nonrandomized study
f patients who received BMT without TBI [10].
lthough this study also showed a signiﬁcantly
horter duration of hospitalization compared with
istoric controls, no economic analyses were per-
ormed. Even in the same BMT setting, our best-
nd worst-case scenarios show that a more or less
avorable proﬁle may be observed in some hospitals,
ith plausible values ranging between savings of
2,090 and $5,103. Furthermore, although the clin-
cal and quality of life improvements increase the
verall value of palifermin in this population, they
ay vary in other BMT settings as well.
In summary, previous trials have demonstrated a
igniﬁcant decrease in clinically important and costly
utcomes of mucositis with palifermin use and re-
uced duration of hospitalization [8,9]. We have
hown that these reductions may offset the acquisition
ost of the drug in patients with hematologic malig-
ancies who undergo SCT after TBI. The economic
roﬁle in other transplant populations will be affected
y a number of factors including transplant type, mu-
otoxicity of treatment regimen, and patient popula-
t
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Economic Impact of Palifermin 813ion. The economic and clinical impact of palifermin
n these settings warrants further investigation.
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